Boehringer Ingelheim struck a cancer drug development deal with Sino Biopharmaceutical Limited (SBP Group) that includes $358 million in upfront and near-term payments and potential milestone payments of more than $7 billion, according to the report. The pact is described as Boehringer’s second partnership with SBP. The transaction underscores Boehringer’s strategy for building exposure to China-led assets while using global development and commercialization capabilities. For SBP, the deal provides near-term resources and a pathway to later-stage clinical and commercial value. For biopharma operators, the scale of the consideration highlights how licensing remains a primary route to pipeline expansion in oncology—especially for targets and candidates sourced from emerging regional ecosystems.